A new defence technology company, Warhound, has launched with a bold mission: to bio-engineer elite working dogs for military and law enforcement use. The venture combines advanced cloning and genetic engineering, sparking both excitement and debate.
What is Warhound?
Warhound is a new Texas-based defence technology company conceived by Ben Lamm, the entrepreneur behind the ambitious woolly mammoth de-extinction project at Colossal Biosciences, and Palmer Luckey of defence tech firm Anduril. The company recently emerged from stealth with $200 million in seed funding to create what it calls 'a secure domestic supply of healthier, more capable working dogs'. The stated goal is to reduce America's reliance on European breeders, from which the U.S. currently acquires over 80% of its military working dogs. Warhound plans to supply these canines to the U.S. military, law enforcement, and emergency first-response teams, combining biotechnology with advanced training and cybernetic hardware.
The Science Behind the 'Warhounds'
The company's strategy is twofold: cloning and genetic engineering. Warhound will start by taking cell samples from top-performing working dogs—primarily breeds like Belgian Malinois, German Shepherds, and some Labradors—and creating a biobank. Using somatic cell nuclear transfer (SCNT), the same technology used to clone the first dog, Snuppy, in 2005, the company can create genetic copies of these elite animals. The next step involves gene-editing tools like CRISPR. The initial focus is on editing out negative genetic mutations that cause common health problems in these breeds, such as hip dysplasia and some forms of muscle atrophy or vision loss. This could produce healthier, more resilient dogs.
The Promise of Enhanced Canines
The primary goal is to produce healthier dogs that are better suited for demanding missions. By eliminating known genetic health defects, Warhound aims to ensure more dogs successfully make it through rigorous training programs, which can be a significant bottleneck. Beyond health, the company has suggested future enhancements could be possible. Ben Lamm has mentioned the potential to edit for improved agility, longevity, or even enhanced senses by, for example, incorporating olfactory receptor genes from wolves to improve a dog's sense of smell. In addition to the biological enhancements, the dogs will be equipped with advanced hardware developed in partnership with Anduril, potentially including protective armour and technology that allows handlers to get real-time information from the dog's perspective.
The Business of Better Dogs
Warhound is entering a specialised and valuable market. The U.S. Department of Defense's working dog program is a multi-million dollar enterprise, with the Air Force alone budgeting $45 million for its program in 2025. By creating a domestic, vertically integrated supply chain—from genetics to training—Warhound aims to capture a significant portion of this government spending. The highndile investors, including Sequoia Capital and In_Q_Tel (the CIA's venture capital arm), signal strong confidence in the business model. The company is licensing the genetic technology from Colossal Biosciences, creating a synergistic relationship between Lamm's two ventures.
An Ethical and Societal Minefield
The prospect of genetically engineered dogs raises significant ethical questions. While editing out diseases is widely seen as a positive step, the line between therapeutic editing and performance enhancement is thin. Critics worry about the long term, unforeseen consequences of altering an animal's genome. There are also animal welfare concerns. Though Warhound states it is working with the American Humane Society to certify its programs, the idea of creating animals specifically for dangerous work like military operations is a point of contention. Some ethicists argue that this commodifies life and raises questions about consent and the animal's quality of life. The debate touches on issues already present in the world of 'designer dogs', where breeding for aesthetics has sometimes led to unintended health problems.
